

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM: IDX 1017	11874-016-999 417451-999016)

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,440; 11/005,443; 11/005,446; and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: November 20, 2008 By: Maria D. Stahl

Name: MARIA D. STAHL

Position: VICE PRESIDENT, ASSOC. GENERAL COUNSEL

Universita Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM: IDX 1017	11874-016-999 417451-999016)

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,440; 11/005,443; 11/005,446; and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Università Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:

Position:

Certifico in Ufficiale Rogante Sostituto
dell'Università degli Studi di Cagliari
che la firma, apposta in mia presenza dal
Prof. Adolfo Lai nato a Ottana
28.07.1943, Pro Rettore dell'Università
di Cagliari e della cui identità personale
sono certo, è autentica

Università Degli Studi di Cagliari

BIC. 2008

L'Ufficiale Rogante Sostituto
Dr. Michele Filiberto Pisanu

Name:

Position:

Centre National de la Recherche Scientifique

Date: _____ By: _____

Name:

Position:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	LaColla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The owners of the entire interest in the above-identified application, Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique (collectively, "owners"), hereby disclaim the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the statutory terms of any patent granted on pending U.S. Patent Application Nos. 11/005,440; 11/005,443; 11/005,446; and 11/516,928 (the "reference applications"). The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patents granted on the reference applications.

The owners further agree that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

The owners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of any patents granted on the reference applications in the event that said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Ownership of the above-identified application and the reference applications in Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique is demonstrated by virtue of assignments recorded November 11, 2008 at reel 021819 frame 0136; November 11, 2008 at reel 021819 frame 0145; and November 11, 2008 at reel 021819 frame 0149.

The undersigned hereby confirm that they have reviewed the assignments and, to the best of their knowledge and belief, title is in the assignees seeking to take action in this matter and that they are empowered to act on behalf of Idenix Pharmaceuticals, Inc., Universita Degli Studi Di Cagliari and Centre National de la Recherche Scientifique.

The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Idenix Pharmaceuticals, Inc.

Date: _____ By: _____

Name:

Position:

Universita Degli Studi di Cagliari

Date: _____ By: _____

Name:

Position:

Centre National de la Recherche Scientifique

Date: 04 DEC. 2008 By: _____

Name:

Position:

Directeur de la Politique Industrielle

Marc J. LEDOUX

